Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells

Seminars in Cancer Biology

Volumn 13, Issue 6, 2003, Pages 461-472

  Speiser, Daniel E ^a   Pittet, Mikaël J ^a   Rimoldi, Donata ^b   Guillaume, Philippe ^b   Luescher, Immanuel F ^b   Liénard, Danielle ^a,c   Lejeune, Ferdy ^c   Cerottini, Jean Charles ^a,b   Romero, Pedro ^a,b  

^a Hopital Orthopedique de la Suisse Romande   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Biological read out; Cytotoxic T cells; Immune monitoring; Melanoma; Synthetic peptide vaccines

Indexed keywords

AS 02 B; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FREUND ADJUVANT; GLYCOPROTEIN GP 100; GLYCOPROTEIN GP 100[209-217]; GLYCOPROTEIN GP 100[280-288]; GLYCOPROTEIN GP 100[44-59]; GLYCOPROTEIN GP 100[457-466]; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; INFLUENZA MATRIX[58-66]; INTERLEUKIN 2; MAGE A12[170-178]; MAGE A3[168-176]; MAGE A3[271-279]; MELAN A; MELAN A[26-35]; MELAN A[27-35]; MELANOMA VACCINE; MONOCLONAL ANTIBODY; MONOPHENOL MONOOXYGENASE; QS 21; SD 9427; TETANUS TOXOID; TUBERCULIN; TUMOR ANTIGEN; TYROSINASE[1-9]; TYROSINASE[368-376]; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL SPECIFICITY; CLINICAL TRIAL; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG FORMULATION; DRUG SCREENING; ENZYME LINKED IMMUNOSPOT ASSAY; FLUORESCENCE; HELPER CELL; HUMAN; IMMUNE STATUS; IMMUNOGENICITY; LYMPHOCYTE MIGRATION; MELANOMA; METHODOLOGY; PATIENT MONITORING; REPRODUCIBILITY; STANDARD; STANDARDIZATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; TUMOR IMMUNITY; TUMOR IMMUNOLOGY; VACCINATION;

EID: 0742304314     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2003.09.010     Document Type: Review

References (80)

1. Traversari C., van der Bruggen P., Luescher I.F., Lurquin C., Chomez P., Van Pel A.et al. A nonpeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 176:1992;1453.
2. Kawakami Y., Eliyahu S., Sakaguchi K., Robbins P.F., Rivoltini L., Yannelli J.R.et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:1994;347.
3. Wolfel T., Van Pel A., Brichard V., Schneider J., Seliger B., Meyer zum Buschenfelde K.H.et al. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol. 24:1994;759.
4. Kawakami Y., Eliyahu S., Jennings C., Sakaguchi K., Kang X., Southwood S.et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymhocytes associated with in vivo tumor regression. J. Immunol. 154:1995;3961.
5. Wolfel T., Hauer M., Schneider J., Serrano M., Wolfel C., Klehmann-Hieb E.et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science. 269:1995;1281.
6. Robbins P.F., El-Gamil M., Li Y.F., Kawakami Y., Loftus D., Appella E.et al. A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183:1996;1185.
7. Wang R.F., Parkhurst M.R., Kawakami Y., Robbins P.F., Rosenberg S.A. Utilization of an alternative open reading frame of a normal gene generating a novel human cancer antigen. J. Exp. Med. 183:1996;1131.
8. Ikeda H., Lethé B., Lehmann F., Van Baren F., Baurain J.-F., De Smet C.et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity. 6:1997;199.
9. Jäger E., Chen Y.-T., Drijfhout J.W., Karbach J., Ringhoffer M., Jäger D.et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187:1998;265.
10. Huang L.Q., Brasseur F., Serrano A., De Plaen E., van der Bruggen P., Boon T.et al. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma. J. Immunol. 162:1999;6849.
11. Ayyoub M., Stevanovic S., Sahin U., Guillaume P., Servis C., Rimoldi D. et al. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J. Immunol. 168:2002;1717.
12. Clark W.H. Tumour progression and the nature of cancer. Br. J. Cancer. 64:1991;631.
13. Mackensen A., Carcelain G., Viel S., Raynal M.C., Michalaki H., Triebel F.et al. Direct evidence to support the immunosurveillance concept in a human regressive melanoma. J. Clin. Invest. 93:1994;1397.
14. Shilyansky J., Nishimura M.I., Yannelli J.R., Kawakami Y., Jacknin L.S., Charmley P.et al. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines. Proc. Natl. Acad. Sci. USA. 91:1994;2829.
15. thor Straten P., Becker J.C., Seremet T., Brocker E.B., Zeuthen J. Clonal T-cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma. J. Clin. Invest. 98:1996;279.
16. Greten T.F., Jaffee E.M. Cancer vaccines. J. Clin. Oncol. 17:1999;1047.
17. Marchand M., Brichard V., van Baren N., Coulie P.G. Biological and clinical developments in melanoma vaccines. Expert Opin. Biol. Ther. 1:2001;497.
18. Sun Y., Paschen A., Schadendorf D. Cell-based vaccination against melanoma - background, preliminary results, and perspective. J. Mol. Med. 77:1999;593.
19. Herlyn D., Birebent B. Advances in cancer vaccine development. Ann. Med. 31:1999;66.
20. Belli F., Testori A., Rivoltini L., Maio M., Andreola G., Sertoli M.R.et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J. Clin. Oncol. 20:2002;4169.
21. Speiser D.E., Miranda R., Zakarian A., Bachmann M.F., McKall-Faienza K., Odermatt B.et al. Self-antigens expressed by solid tumors do not stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. 186:1997;645.
22. Speiser D.E., Ohashi P.S. Activation of cytotoxic T cells by solid tumours? Cell Mol. Life Sci. 54:1998;263.
23. Marchand M., Van Baren N., Weynants P., Brichard V., Dréno B., Tessier M.H.et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer. 80:1999;219.
24. Jäger E., Bernhard H., Romero P., Ringhoffer M., Arand M., Karbach J.et al. Generation of cytotoxic T cell responses with synthetic melanoma associated peptides in vivo, implications for tumor vaccines with melanoma associated antigens. Int. J. Cancer. 66:1996;162.
25. Cormier J.N., Salgaller M.L., Prevette T., Barracchini K.C., Rivoltini L., Restifo N.P.et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J. Sci. Am. 3:1997;37.
26. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., Topalian S.L.et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:1998;321.
27. Smith J.W. 2nd, Walker E.B., Fox B.A., Haley D., Wisner K.P., Doran T.et al. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J. Clin. Oncol. 21:2003;1562.
28. Valmori D., Gileadi U., Servis C., Dunbar P.R., Cerottini J.C., Romero P.et al. Modulation of proteasomal activity required for the generation of a CTL-defined peptide derived from the tumor antigen MAGE-3. J. Exp. Med. 189:1999;895.
29. Ayyoub M., Migliaccio M., Guillaume P., Lienard D., Cerottini J.-C., Romero P.et al. Lack of tumor recognition by hTERT peptide 540-548-specific CD8+ T cells from melanoma patients reveals inefficient antigen processing. Eur. J. Immunol. 31:2001;2642.
30. Speiser D.E., Cerottini J.C., Romero P. Can hTERT peptide (540-548)-specific CD8 T cells recognize and kill tumor cells? Cancer Immun. 2:2002;14.
31. Speiser D.E., Liénard D., Pittet M.J., Batard P., Guillaume P., Lejeune F.et al. In vivo activation of melanoma specific CD8+ T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus specific T cells. Eur. J. Immunol. 32:2002;731.
32. Restifo N.P., Overwijk W.W. Creating therapeutic cancer vaccines: notes from the battlefield. Immunol. Today. 22:2001;5.
33. Ochsenbein A.F., Sierro S., Odermatt B., Pericin M., Karrer U., Hermans J.et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature. 411:2001;1058.
34. Cohen E.P., Kim T.S. Neoplastic cells that express low levels of MHC class I determinants escape host immunity. Semin. Cancer Biol. 5:1994;419.
35. Cromme F.V., Airey J., Heemels M.T., Ploegh H.L., Keating P.J., Stern P.L.et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J. Exp. Med. 179:1994;335.
36. Jäger E., Ringhoffer M., Karbach J., Arand M., Oesch F., Knuth A. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int. J. Cancer. 66:1996;470.
37. Garrido F., Ruiz-Cabello F., Cabrera T., Perez-Villar J.J., Lopez-Botet M., Duggan-Keen M.et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today. 18:1997;89.
38. Marincola F.M., Jaffee E.M., Hicklin D.J., Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74:2000;181.
39. 51Cr -labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs Immunology. 14:1968;181.
40. Blomberg K., Ulfstedt A.C. Fluorescent europium chelates as target cell markers in the assessment of natural killer cell cytotoxicity. J. Immunol. Methods. 160:1993;27.
41. Kaminski E., Sharrock C., Hows J., Ritter M., Arthur C., McKinnon S.et al. Frequency analysis of cytotoxic T lymphocyte precursors: possible relevance to HLA-matched unrelated donor bone marrow transplantation. Bone Marrow Transpl. 3:1988;149.
42. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies I. Data analysis. J. Immunol. 126:1981;1614.
43. Coulie P.G., Karanikas V., Colau D., Lurquin C., Landry C., Marchand M. et al. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc. Natl. Acad. Sci. USA. 98:2001;10290.
44. Maino V.C., Picker L.J. Identification of functional subsets by flow cytometry: intracellular detection of cytokine expression. Cytometry. 34:1998;207.
45. Herr W., Schneider J., Lohse A.W., Meyer zum Buschenfelde K.H., Wölfel T. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. J. Immunol. Methods. 191:1996;131.
46. Casanova J.L., Maryanski J.L. Antigen-selected T-cell receptor diversity and self-nonself homology. Immunol. Today. 14:1993;391.
47. Cole G.A., Hogg T.L., Woodland D.L. The MHC class I-restricted T cell response to Sendai virus infection in C57BL/6 mice: a single immunodominant epitope elicits an extremely diverse repertoire of T cells. Int. Immunol. 6:1994;1767.
48. Romero P., Pannetier C., Herman J., Jongeneel C.V., Cerottini J.C., Coulie P.G. Multiple specificities in the repertoire of a melanoma patient's cytolytic T lymphocytes directed against tumor antigen MAGE-1.A1. J. Exp. Med. 182:1995;1019.
49. Dietrich P.Y., Walker P.R., Quiquerez A.L., Perrin G., Dutoit V., Lienard D.et al. Melanoma patients respond to a cytotoxic T lymphocyte-defined self-peptide with diverse and nonoverlapping T-cell receptor repertoires. Cancer Res. 61:2001;2047.
50. Altman J.D., Moss P.A.H., Goulder P.J.R., Barouch D.H., McHeyzer-Williams M.G., Bell J.I.et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 274:1996;94.
51. Greten T.F., Slansky J.E., Kubota R., Soldan S.S., Jaffee E.M., Leist T.P.et al. Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19-specific CD8+ T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. Proc. Natl. Acad. Sci. USA. 95:1998;7568.
52. Romero P., Dunbar P.R., Valmori D., Pittet M.J., Ogg G.S., Rimoldi D.et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytotoxic T lymphocytes. J. Exp. Med. 188:1998;1641.
53. Skinner P.J., Daniels M.A., Schmidt C.S., Jameson S.C., Haase A.T. Cutting edge: in situ tetramer staining of antigen-specific T cells in tissues. J. Immunol. 165:2000;613.
54. Haanen J.B., van Oijen M.G., Tirion F., Oomen L.C., Kruisbeek A.M., Vyth-Dreese F.A.et al. In situ detection of virus-and tumor-specific T-cell immunity. Nat. Med. 6:2000;1056.
55. Andersen M.H., Pedersen L.O., Becker J.C., Straten P.T. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res. 61:2001;869.
56. Pittet M.J., Speiser D.E., Liénard D., Valmori D., Guillaume P., Dutoit V.et al. Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. Clin. Cancer Res. 7:2001;796.
57. Valmori D., Dutoit V., Schnuriger V., Quiquerez A.L., Pittet M.J., Guillaume P.et al. Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity. J. Immunol. 168:2002;4231.
58. Janssen E.M., Lemmens E.E., Wolfe T., Christen U., von Herrath M.G., Schoenberger S.P. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 421:2003;852.
59. Sun J.C., Bevan M.J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science. 300:2003;339.
60. Shedlock D.J., Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science. 300:2003;337.
61. Bourgeois C., Rocha B., Tanchot C. A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science. 297:2002;2060.
62. Clay T.M., Hobeika A.C., Mosca P.J., Lyerly H.K., Morse M.A. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin. Cancer Res. 7:2001;1127.
63. Brosterhus H., Brings S., Leyendeckers H., Manz R.A., Miltenyi S., Radbruch A.et al. Enrichment and detection of live antigen-specific CD4(+) and CD8(+) T cells based on cytokine secretion. Eur. J. Immunol. 29:1999;4053.
64. Novak E.J., Liu A.W., Nepom G.T., Kwok W.W. MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen. J. Clin. Invest. 104:1999;R63.
65. Wang F., Bade E., Kuniyoshi C., Spears L., Jeffery G., Marty V.et al. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin. Cancer Res. 5:1999;2756.
66. Pullarkat V., Lee P.P., Scotland R., Rubio V., Groshen S., Gee C.et al. A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clin. Cancer Res. 9:2003;1301.
67. Pass H.A., Schwarz S.L., Wunderlich J.R., Rosenberg S.A. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J. Sci. Am. 4:1998;316.
68. *A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. Clin. Cancer Res. 8:2002;967.
69. Weber J.S., Hua F.L., Spears L., Marty V., Kuniyoshi C., Celis E. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. J. Immunother. 22:1999;431.
70. Lee P., Wang F., Kuniyoshi J., Rubio V., Stuges T., Groshen S.et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J. Clin. Oncol. 19:2001;3836.
71. Scheibenbogen C., Schmittel A., Keilholz U., Allgauer T., Hofmann U., Max R.et al. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J. Immunother. 23:2000;275.
72. Phan G.Q., Touloukian C.E., Yang J.C., Restifo N.P., Sherry R.M., Hwu P.et al. Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J. Immunother. 26:2003;349.
73. *0702- associated epitope MAGE-A12:170-178. Int. J. Cancer. 105:2003;210.
74. Tanaka S., Harada M., Mine T., Noguchi M., Gohara R., Azuma K.et al. Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific ctotoxic T-lymphocyte precursors in the periphery. J. Immunother. 26:2003;357.
75. Phan G.Q., Yang J.C., Sherry R.M., Hwu P., Topalian S.L., Schwartzentruber D.J.et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci USA. 100:2003;8372.
76. Thurner B., Haendle I., Roder C., Dieckmann D., Keikavoussi P., Jonuleit H.et al. Vaccination with MAGE-3.A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190:1999;1669.
77. Schuler-Thurner B., Dieckmann D., Keikavoussi P., Bender A., Maczek C., Jonuleit H.et al. MAGE-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J. Immunol. 165:2000;3492.
78. Banchereau J., Palucka A.K., Dhodapkar M., Burkeholder S., Taquet N., Rolland A.et al. Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res. 61:2001;6451.
79. Gajewski T.F., Fallarino F., Ashikari A., Sherman M. Immunization of HLA-A2+ melanoma patients with MAGE-3 or Melan-A peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin. Cancer Res. 7:2001;895s.
80. Peterson A.H.H., Gajewski T.F. Immunization with Melan-A pepetide-pulsed peripheral blood monocellular cells plus recombinant interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J. Clin. Oncol. 21:2003;2342.